Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting

Leukemia

Volumn 15, Issue 9, 2001, Pages 1408-1414

  Varella Garcia, M ^a   Hogan, C J ^a   Odom, L F ^b   Murata Collins, J L ^c   Ai, H ^a,d   Chen, L ^a   Richkind, K ^e   Paskulin, G ^f   Andreeff, M ^g   Brizard, A ^h   Mcgavran, L ⁱ   Gemmill, R M ^a   Berger, R ^j   Drabkin, H A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d SUN YAT SEN UNIVERSITY   (China)

^e GENZYME GENETICS   (United States)

^f UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h POITIERS UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j INSERM   (France)

more..

Author keywords

Acute myeloid leukemia; AML1; Chromosome translocation; ETO

Indexed keywords

CD34 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ARTICLE; CANCER RECURRENCE; CELL SELECTION; CHROMOSOME 22Q; CHROMOSOME 8Q; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA REMISSION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 17944371518     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402219     Document Type: Article

References (25)

1. Cytogenetics in acute myeloid leukaemia
2. The AML1 and ETO genes in acute myeloid leukemia with a t(8;21)
3. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt
4. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript
5. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia
6. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation
7. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission
8. AML1/ETO-expressing non-leukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation
9. Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR
10. Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia
11. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay
12. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse
13. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: A metaphase-FISH study
14. Assessing residual leukemia through fluorescence in situ hybridization (FISH)
15. Pre-clinical evaluation of probes to detect t(8;21) AML minimal residual disease by fluorescence in situ hybridization
16. Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia
17. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia
18. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: Correlation with cytogenetics, morphology and immunophenotype
19. Cellular characteristics of acute myeloblastic leukemia associated with t(8;21)(q22;q22)
20. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL
21. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon
22. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model
23. Haploinsufficiency of AML1 effects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo
24. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
25. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice